The treatment of Dex-SA-CDDP-LHRH led to a substantial augmentation in the accumulation of CDDP within both the primary tumor and the organs harboring metastases, resulting in a significant decrease in the nephrotoxic impacts of CDDP. This evidence concerns the gene GNRH1 and neoplasm.